A ntiplatelet therapeutics are a mainstay of primary and secondary prevention strategies for thrombotic cardiovascular and neurovascular diseases. Currently available agents, aspirin and thienopyridines, directly target platelet activation pathways mediated by thromboxane A2 (the major metabolic product of platelet cyclooxygenase) and ADP. These critical pathways are responsible for amplifying platelet responses to vascular injury, and although this pharmacological approach has proven to be effective and safe, it is not perfect; many patients experience thrombotic events despite taking these drugs, and many experience bleeding complications. Exploiting novel targets to improve efficacy is, thus, an important avenue of translational research.
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In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Yeung et al 1 provide compelling evidence that targeting metabolic pathways downstream of a specific long-chain polyunsaturated fatty acid, ω-6-dihomoγ-linoleic acid (DGLA), could provide thromboprotection by activating intracellular platelet inhibitory pathway(s) that represent a natural braking system triggered normally by endogenous soluble mediators, such as prostacyclin and nitric oxide. 2 The authors used a combination of pharmacological and genetic approaches to study activation of washed platelets ex vivo along with mouse in vivo models of thrombosis and hemostasis. They showed that DGLA inhibited platelet activation by classic agonists (collagen and thrombin) and that this required the intracellular enzyme 12-lipoxygenase (LOX). The active metabolic product generated from DGLA by 12-LOX, 12(S)-hydroxy-8Z,10E14Zeicosatetrienoic acid (12-HETrE), was then shown to inhibit platelet activation ex vivo and to blunt platelet and fibrin accumulation in a laser-induced arteriolar injury model in vivo. As predicted, the effect of 12-HETrE was not dependent on 12-LOX. Other polyunsaturated fatty acids, such as arachidonic and linoleic acid, did not produce this antiplatelet, antithrombotic effect, presumably because they do not generate 12-HETrE from the action of 12-LOX. DGLA is not abundant in platelet membranes, and 12-HETrE was not detected in activated platelets, suggesting that neither DGLA nor 12-HETrE plays a role in normal platelet function and that it is the substrate, not the enzyme, that is the limiting agent in this pathway.
This work extends a story that began >40 years ago when investigators first showed that DGLA had antiplatelet activity. 3 It also relates to longstanding interest by investigators in the field of cardioprevention to develop interventions based on nutritional approaches, such as fish oils, as sources of ω-polyunsaturated fatty acids. By tying DGLA antiplatelet activity to a specific pharmacology, 12-LOX mediated generation of a specific downstream metabolic product, which then acts at the receptor level to blunt platelet activation and thrombus formation, Yeung et al have significantly advanced the field. Furthermore, by showing that 12-HETrE acts through an as yet unidentified Gα s -linked receptor to activate the cAMP-mediated platelet brake, the authors raise the possibility that additional targets could be found to activate this pathway.
Much more needs to be done to translate this discovery to potential clinical utility, including demonstration of efficacy in animal model systems involving large arteries, such as carotid and coronary, that are more relevant to atherothrombosis than the arteriolar model used by Yeung et al. In addition, the authors suggest that 12-HETrE did not negatively impact normal hemostasis, meeting criteria for the holy grail of antithrombotic therapy-preventing pathological thrombosis while not increasing the risk of untoward bleeding. A close look at their data, however, does not fully support the claim. The hemostasis assays used, time for bleeding to stop after distal excision of 5 mm of tail or after arteriolar puncture induced by laser, are crude, and in fact, their data show a 15% to 20% increase in mean tail bleeding times and 40% increase in mean arteriolar bleeding times. This is consistent with the hemostatic defect reported in 12-LOX null mice. 4 It is highly likely that these assays were underpowered to detect small defects in hemostasis that in large populations treated for long periods would likely have clinical relevance.
Mechanistically, key unanswered questions include the identity of the 12-HETrE receptor, as well as its downstream signaling partners. Furthermore, 12-LOX plays complex roles in many cell types, including leukocytes and platelets, and shuttling of substrates from one cell to another-socalled transcellular metabolism-during atherothrombotic and inflammatory processes could generate a portfolio of
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Arterioscler Thromb Vasc Biol October 2016 bioactive oxylipins that could influence platelet, vascular, and inflammatory functions in ways not predicted by the simple model systems used by Yeung et al. Because many patients with vascular disease or at high risk for vascular disease take aspirin, the impact of COX inhibition on substrate availability for 12-LOX could add to the complexity. Nevertheless, the work by Yeung et al has provided strong rationale to continue exploration of the DGLA/12-LOX system in greater depth, both mechanistically and in clinical models.
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